AlloCSC-01

Developed for: acute myocardial infarction
Investigated by: Complejo Hospitalario de Navarra · Coretherapix · European Commission · Hospital Clínico Universitario de Valencia · Hospital Clínico Universitario de Valladolid · Hospital Donostia
+5 more
· Hospital General Universitario Gregorio Marañon · Hospital Universitario Virgen de la Victoria · Saint-Louis Hospital, Paris, France · Universitaire Ziekenhuizen KU Leuven · University of Salamanca

today NCT02439398 · Ph 1/2

2015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT02439398	Jun 2014 → Dec 2015	acute myocardial infarction	Coretherapix	Completed	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	AlloCSC-01	“RATIONALE: Allogeneic cardiac stem cells (AlloCSC-01) have shown protective, immunoregulatory, and regenerative properties with a robust safety profile in large animal models...” PMID 29921651 ↗ Aug 2018
Modality	Cell therapy	“indicating their suitability as a cell therapy product.” PMID 31151405 ↗ May 2019
Route	Other	“the intracoronary administration of a suspension of allogeneic cardiac stem cells (CSCs)” NCT02439398 ↗